Infectious disease diagnostics
6 European H2020 organizations list this as part of their work — 3 as their primary capability.
Most active in this area
- THE UNIVERSITY OF STIRLING
Scottish university strong in aquaculture science, water quality monitoring, and food-biodiversity trade-offs, with growing environmental observation capabilities.
“EbolaMoDRAD and VHFMoDRAD focus on rapid bedside diagnostics for viral haemorrhagic fevers, including Ebola.”
UK38 projects - BIOMERIEUX SA
Global in-vitro diagnostics company contributing infectious disease detection, AMR testing, and precision molecular diagnostics to European health research consortia.
“Central theme across PERFORM, ND4ID, DIAMONDS, VALUE-Dx, COMBACTE-CDI, ImmunoSep, and VITAL — all focused on diagnosing or managing infectious diseases.”
PrimaryFR11 projects - TATAA BIOCENTER AB
Swedish SME specializing in PCR-based molecular diagnostics, multi-omics biomarker validation, and point-of-care test development for health research consortia.
“TB diagnostics (PITBUL), sepsis diagnosis (SMARTDIAGNOS), and COVID-19 rapid testing (CORONADX) cover bacterial, systemic, and viral infections respectively.”
SMESE7 projects - FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS
Global non-profit accelerating infectious disease diagnostics — from clinical validation and AI-driven trials to wearable detection technology.
“Core thread across Mofina (filovirus testing), VALUE-Dx (antimicrobial resistance diagnostics), UNITE4TB (tuberculosis treatment), and EUROLEISH-NET (leishmaniasis).”
PrimaryCH5 projects - BIOVENDOR - LABORATORNI MEDICINA AS
Czech diagnostics SME developing biomarker assays, point-of-care devices, and reagent kits for infection, cancer, and neurodegeneration research.
“DIAGORAS addressed oral and respiratory tract infections with antibiotic resistance identification from saliva samples.”
PrimarySMECZ3 projects - ACOBIOM
French biotech SME specializing in biomarker discovery and in vitro diagnostic development for cancer, psychiatric, and infectious diseases.
“LeiSHield-MATI involved prognostic and diagnostic tools for leishmaniasis, including immune response profiling.”
SMEFR3 projects